Jump to content

Galnon: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
CheMoBot (talk | contribs)
Updating {{drugbox}} (changes to verified and watched fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report [[Wikipedia t...
changed chembl id
Line 35: Line 35:
| DrugBank =
| DrugBank =
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 451433
| ChEMBL = 592414


<!--Chemical data-->
<!--Chemical data-->

Revision as of 12:44, 23 January 2012

Galnon
Identifiers
  • 9H-​fluoren-​9-​ylmethyl N-​[(2S)-​1-​([(2S)-​6-​amino-​1-​[(4-​methyl-​2-​oxochromen-​7-​ yl)amino]-​1-​oxohexan-​2-​yl]amino)-​3-cyclohexyl-​1-​oxopropan-​2-​yl]carbamate
CAS Number
PubChem CID
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC40H46N4O6
Molar mass678.815 g·mol−1
3D model (JSmol)
  • Cc3cc(=O)oc6cc(ccc36)NC(=O)C(CCCCN)NC(=O)C(CC5CCCCC5)NC(=O)OCC1c2ccccc2-c4c1cccc4
 ☒NcheckY (what is this?)  (verify)

Galnon is a drug which acts as a selective, non-peptide agonist at the galanin receptors GALR.[1][2] It has anticonvulsant, anxiolytic, anorectic and amnestic effects in animal studies.[3][4][5][6][7]


References

  1. ^ Saar K, Mazarati AM, Mahlapuu R, Hallnemo G, Soomets U, Kilk K, Hellberg S, Pooga M, Tolf BR, Shi TS, Hökfelt T, Wasterlain C, Bartfai T, Langel U (2002). "Anticonvulsant activity of a nonpeptide galanin receptor agonist". Proceedings of the National Academy of Sciences of the United States of America. 99 (10): 7136–41. doi:10.1073/pnas.102163499. PMC 124541. PMID 12011470. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. ^ Sollenberg U, Bartfai T, Langel U (2005). "Galnon--a low-molecular weight ligand of the galanin receptors". Neuropeptides. 39 (3): 161–3. doi:10.1016/j.npep.2004.12.019. PMID 15944006. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  3. ^ Abramov U, Florén A, Echevarria DJ, Brewer A, Manuzon H, Robinson JK, Bartfai T, Vasar E, Langel U (2004). "Regulation of feeding by galnon". Neuropeptides. 38 (1): 55–61. doi:10.1016/j.npep.2004.01.001. PMID 15003717. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  4. ^ Badie-Mahdavi H, Behrens MM, Rebek J, Bartfai T (2005). "Effect of galnon on induction of long-term potentiation in dentate gyrus of C57BL/6 mice". Neuropeptides. 39 (3): 249–51. doi:10.1016/j.npep.2004.12.010. PMID 15944018. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  5. ^ Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE (2007). "Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon". Neuropeptides. 41 (5): 307–20. doi:10.1016/j.npep.2007.05.001. PMID 17637475. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  6. ^ Kozlovsky N, Matar MA, Kaplan Z, Zohar J, Cohen H (2009). "The role of the galaninergic system in modulating stress-related responses in an animal model of posttraumatic stress disorder". Biological Psychiatry. 65 (5): 383–91. doi:10.1016/j.biopsych.2008.10.034. PMID 19095221. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  7. ^ Narasimhaiah R, Kamens HM, Picciotto MR (2009). "Effects of galanin on cocaine-mediated conditioned place preference and ERK signaling in mice". Psychopharmacology. 204 (1): 95–102. doi:10.1007/s00213-008-1438-7. PMC 2872184. PMID 19099295. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

Template:Neuropeptide agonists and antagonists